Literature DB >> 24565700

The variable in common variable immunodeficiency: a disease of complex phenotypes.

Stephen Jolles1.   

Abstract

Common variable immunodeficiency (CVID) is the most common and clinically most important severe primary antibody deficiency and is characterized by low levels of IgG, IgA, and/or IgM, with a failure to produce specific antibodies. This diagnostic category represents a heterogeneous group of disorders, which present not only with acute and chronic infections but also with a range of inflammatory and autoimmune disorders as well as an increased incidence of lymphoma and other malignancies. Patients can now be categorized into distinct clinical phenotypes based on analysis of large cohort studies and be further stratified by immunologic laboratory testing. The biologic importance of this categorization is made clear by the 11-fold increase in mortality if even one of these phenotypes (cytopenias, lymphoproliferation, or enteropathy) is present. Limited progress in defining the underlying molecular causes has been made with known causative single gene defects accounting for only 3% of cases, and, for this and the reasons mentioned above, CVID remains resolute in its variability. This review provides a practical approach to risk stratification of these complex phenotypes by using current clinical categories and laboratory biomarkers. The effects of infection as well as inflammatory and autoimmune complications on different organ systems are discussed alongside strategies to reduce diagnostic delay. Recent developments in diagnostics and therapy are also explored.
Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody deficiency; Biomarker; Common variable immunodeficiency; Immunoglobulin; Primary immunodeficiency

Mesh:

Substances:

Year:  2013        PMID: 24565700     DOI: 10.1016/j.jaip.2013.09.015

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  39 in total

1.  Progression of Common Variable Immunodeficiency Interstitial Lung Disease Accompanies Distinct Pulmonary and Laboratory Findings.

Authors:  Paul J Maglione; Jessica R Overbey; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2015-09-12

2.  Immunoglobulins: current understanding and future directions.

Authors:  S Jolles; S C Jordan; J S Orange; I N van Schaik
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

3.  Subclinical infection and dosing in primary immunodeficiencies.

Authors:  S Jolles
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

4.  Common variable immunodeficiency (CVID): new genetic insight and unanswered questions.

Authors:  H D Ochs
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 5.  Chronic Diarrhea in Common Variable Immunodeficiency: a Case Series and Review of the Literature.

Authors:  Antonio Pecoraro; Liliana Nappi; Ludovica Crescenzi; Francesco P D'Armiento; Arturo Genovese; Giuseppe Spadaro
Journal:  J Clin Immunol       Date:  2017-11-14       Impact factor: 8.317

6.  FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID).

Authors:  S Jolles; E Carne; M Brouns; T El-Shanawany; P Williams; C Marshall; P Fielding
Journal:  Clin Exp Immunol       Date:  2016-11-28       Impact factor: 4.330

7.  Neurologic Conditions and Symptoms Reported Among Common Variable Immunodeficiency Patients in the USIDNET.

Authors:  Michael Lee; Jenna Nguyen; Ramsay Fuleihan; Katherine Gundling; Charlotte Cunningham-Rundles; Iris M Otani
Journal:  J Clin Immunol       Date:  2020-09-08       Impact factor: 8.317

Review 8.  When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.

Authors:  S Jolles; H Chapel; J Litzman
Journal:  Clin Exp Immunol       Date:  2017-01-30       Impact factor: 4.330

Review 9.  Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.

Authors:  S Jolles; J S Orange; A Gardulf; M R Stein; R Shapiro; M Borte; M Berger
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

Review 10.  Autoimmune and Lymphoproliferative Complications of Common Variable Immunodeficiency.

Authors:  Paul J Maglione
Journal:  Curr Allergy Asthma Rep       Date:  2016-03       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.